GSK2585823(CLDM 1%-BPO 3% gel) — Competitive Intelligence Brief

GSK2585823(CLDM 1%-BPO 3% gel) (GSK2585823(CLDM 1%-BPO 3% gel)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic combination. Area: Dermatology.

phase 3 Topical antibiotic combination Bacterial protein synthesis (clindamycin); oxidative antimicrobial activity (benzoyl peroxide) Dermatology Small molecule

Target snapshot

GSK2585823(CLDM 1%-BPO 3% gel) (GSK2585823(CLDM 1%-BPO 3% gel)) — GlaxoSmithKline. This combination gel delivers clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial and keratolytic agent) topically to reduce acne-causing bacteria and inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GSK2585823(CLDM 1%-BPO 3% gel) TARGET	GSK2585823(CLDM 1%-BPO 3% gel)	GlaxoSmithKline	phase 3	Topical antibiotic combination	Bacterial protein synthesis (clindamycin); oxidative antimicrobial activity (benzoyl peroxide)
clindamycin 1% / benzoyl peroxide 5% tube	clindamycin 1% / benzoyl peroxide 5% tube	Sanofi	marketed	Topical antibiotic combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Mupirocin + Chlorhexidin	Mupirocin + Chlorhexidin	B. Braun Medical SA	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
Acnatac® Gel left face	Acnatac® Gel left face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide)
BENZOYL PEROXIDE/ CLINDAMYCIN	BENZOYL PEROXIDE/ CLINDAMYCIN	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Polysporin Ointment	Polysporin Ointment	University of British Columbia	marketed	Topical antibiotic combination	Bacterial cell wall (bacitracin) and bacterial cell membrane (polymyxin B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic combination class)

1. Stiefel, a GSK Company · 3 drugs in this class
2. GlaxoSmithKline · 3 drugs in this class
3. GWT-TUD GmbH · 2 drugs in this class
4. Sun Pharmaceutical Industries, Inc. · 1 drug in this class
5. University Health Network, Toronto · 1 drug in this class
6. University of British Columbia · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. B. Braun Medical SA · 1 drug in this class
9. Watson Laboratories, Inc. · 1 drug in this class
10. Padagis LLC · 1 drug in this class